Who was studied in CBL-514 abdominal-fat trials?

The NCT05736107 registry record describes adults aged 18–64, body mass index above 18.5 and below 30 kg/m², and clinician-rated Grade 3 or 4 abdominal subcutaneous fat at screening. It also required stable body weight and lifestyle before and during the study. These criteria define the setting in which the 2026 Phase 2b publication should be read. An outcome measured in that group is not automatically a finding for all ages, body sizes, anatomical areas or weight-loss goals.

The trial record names exclusions relevant to interpretation, including Dercum disease and other lipomatosis syndromes, previous treatment-area contouring procedures within specified windows, and use of GLP-1 agonists within its stated window. Those restrictions are study-design choices, not a list of medical recommendations. They reduce ambiguity for a particular question but also limit where the result can be generalized. Always read the current registry version with the paper because entry criteria and dates can be amended.

Abdominal subcutaneous fat, Dercum disease lipomas and cellulite involve different populations and endpoints. The abdominal Phase 2b registry specifically excludes lipomatosis syndromes such as Dercum disease. A separate Dercum disease study record addresses painful lipomas under its own criteria. The existence of one program does not transfer its results to another. A cosmetic appearance scale, MRI abdominal fat measurement, pain score and lipoma-volume measurement should keep their original study identifiers.

The earlier 2025 abdominal Phase II report used a different BMI ceiling and an ultrasound-based volume endpoint. It also noted that its participants were mainly Caucasian and called for study in other ethnic groups. That statement is a limitation from the authors, not proof that effects differ by ethnicity. When summarizing the program, separate each publication’s eligibility, follow-up and endpoint before making a cross-study statement. A broad “CBL-514 trial” label hides these distinctions.

Trial criteria tell a reader who was studied under an investigational protocol. They do not identify the contents of a commercial research vial or authorize administration outside a trial. A product photo, label or seller description cannot borrow the trial’s population and safety observations simply by using the same development name. The clinical-versus-research guide explains the boundary; the vial-photo guide explains what visual evidence does and does not establish.

For a literature review, extract a compact eligibility table: indication, age, relevant baseline measure, key exclusions, geography, and the endpoint used to judge response. For procurement, write a different table: legal supplier, substance definition, batch identifier, analytical method and intended laboratory use. Combining those tables makes a source look more complete than it is. Record the date you checked the registry and return to its history for later changes. This article describes published research boundaries, not medical screening guidance.